BrainStorm Stem Cell Treatment Succeeds In ALS Trial

Israeli stem cell therapeutics company BrainStorm Cell Therapeutics Ltd., which develops adult stem cell therapeutics for neurodegenerative diseases, has announced success in a clinical trial on ALS patients. 36 patients treated with the company’s stem cell treatment NurOwn exhibited slower degeneration than the twelve patients in the control group. Founded in 2004 and now led by Chaim Lebovits, BrainStorm is developing treatments for Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).